Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

65.04USD
25 May 2017
Change (% chg)

-- (--)
Prev Close
$65.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,484,241
52-wk High
$66.80
52-wk Low
$55.10

MRK

Chart for MRK

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $177,895.09
Shares Outstanding(Mil.): 2,735.17
Dividend: 0.47
Yield (%): 2.89

Financials

  MRK Industry Sector
P/E (TTM): 41.67 14.35 17.42
EPS (TTM): 1.56 -- --
ROI: 5.54 -7.29 -5.45
ROE: 10.39 -6.80 -4.73

BRIEF-Optum and Merck collaborate to advance value-based contracting of pharmaceuticals

* Optum and merck collaborate to advance value-based contracting of pharmaceuticals

May 25 2017

BRIEF-Merck enters exclusive worldwide license agreement with Teijin Pharma

* Merck enters exclusive worldwide license agreement with Teijin Pharma for investigational antibody candidate targeting TAU

May 25 2017

FDA clears Merck's Keytruda based on cancer genetics, not location

Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits, regardless of where in the body the disease originated.

May 23 2017

UPDATE 2-FDA clears Merck's Keytruda based on cancer genetics, not location

May 23 Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits, regardless of where in the body the disease originated.

May 23 2017

FDA clears Merck's Keytruda for cancer patients with certain biomarkers

The U.S. Food and Drug Administration on Tuesday approved Merck & Co's immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature.

May 23 2017

UK competition watchdog accuses Merck of obstructing biosimilars

LONDON Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.

May 23 2017

FDA clears Merck's Keytruda for cancer patients with certain biomarkers

May 23 The U.S. Food and Drug Administration on Tuesday approved Merck & Co's immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature.

May 23 2017

BRIEF-Merck sets quarterly dividend of $0.47 per share

* Sets quarterly dividend of $0.47 per share Source text for Eikon: Further company coverage:

May 23 2017

UK competition watchdog accuses Merck of obstructing biosimilars

LONDON Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.

May 23 2017

UPDATE 2-UK competition watchdog accuses Merck of obstructing biosimilars

* CMA can fine companies up to 10 pct of global turnover (Adds details on past fines, more on biosimilars market)

May 23 2017

More From Around the Web

Competitors

Earnings vs. Estimates